The clinical significance of soluble E-cadherin in lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 769s Year: 2006
The role of CD40 molecule in human lung cancer and its application in immunotherapy Source: Eur Respir J 2003; 22: Suppl. 45, 199s Year: 2003
The expression and biological significance of PD-L1 on lung cancer cell lines Source: Annual Congress 2009 - Lung cancer biology Year: 2009
The effect of adhesion molecule CEACAM1 and chemokine receptor CXCR4 expression on prognosis of non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005
Clinical significance of circulating KL-6/MUC1 carrying selectin ligands in patients with lung adenocarcinoma Source: Eur Respir J 2006; 28: Suppl. 50, 388s Year: 2006
Clinical significance of serum cathepsin K level during chemotherapy of lung cancer. Can we use it as a marker of small cell lung cancer? Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Prognostic value of circulating MUC1/KL-6 with selectin ligands in patients with lung adenocarcinoma Source: Eur Respir J 2005; 26: Suppl. 49, 481s Year: 2005
Soluble NKG2D ligand expression associates with smoking, presence of COPD, and presence of lung cancer: The "EMICON" study Source: Annual Congress 2010 - Lung morbidity on exposure to various agents Year: 2010
Prognostic and potential therapeutic impact of prostate specific membrane antigen expression in non-small cell lung cancer Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Expression and significance of VE-cadherin and E-cadherin in non-small cell lung cancer Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker Source: International Congress 2019 – Biology of lung cancer Year: 2019
Clinicopathological significance and prognostic importance of circulating plasma DNA expression in advanced non-small cell lung cancer and its efficacy as a diagnostic tool Source: Annual Congress 2012 - New insights in the pathology of lung cancer Year: 2012
Vitronectin expression in primary lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011
The value of CD44 and MMP-2 expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008
Expression of vascular endothelial-cadherin and epithelial cadherin in non-small cell lung cancer and their clinical significances Source: Annual Congress 2012 - New aspects of lung cancer biology Year: 2012
The expression and clinical significance of PD-L1+ CD68+ macrophages in peripheral blood mononuclear cells of non-small cell lung cancer Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer Source: Annual Congress 2009 - Lung cancer biology Year: 2009